Alzheimer’s Disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss and cognitive impairment, affecting 35 million individuals worldwide. Intracerebroventricular (ICV) injection of low to moderate doses of streptozotocin (STZ) in adult male Wistar rats can reproduce classical physiopathological hallmarks of AD. This biological model is known as ICV-STZ. Most studies are focused on the description of behavioral and morphological aspects of the ICV-STZ model. However, knowledge regarding the molecular aspects of the ICV-STZ model is still incipient. Therefore, this work is a first attempt to provide a wide proteome description of the ICV-STZ model based on mass spectrometry (MS). To achieve that, samples from the pre-frontal cortex (PFC) and hippocampus (HPC) of the ICV-STZ model and control (wild-type) were used. Differential protein abundance, pathway, and network analysis were performed based on the protein identification and quantification of the samples. Our analysis revealed dysregulated biological pathways implicated in the early stages of late-onset Alzheimer’s disease (LOAD), based on differentially abundant proteins (DAPs). Some of these DAPs had their mRNA expression further investigated through qRT-PCR. Our results shed light on the AD onset and demonstrate the ICV-STZ as a valid model for LOAD proteome description.
16 May 2018 in Journal of Pharmacy and Pharmacology
The beneficial effect of polyphenols and magnesium(II) against oxidative stress motivated our research group to explore the antioxidant activity of phenMgIso, an aqueous soluble magnesium(II) complex containing 1,10-phenanthroline (phen) and isovanillic acid (Iso) as ligands. Combined electrospray ionization–mass spectrometry and DOSY-NMR techniques identified two complexes in methanolic solution: hexacoordinated [Mg(phen)2(Iso)]+ and tetracoordinated [Mg(phen)(Iso)]+. The cyclic voltammogram of phenMgIso in the anodic region showed a cyclic process that interrupts the isovanillic acid degradation, probably by stabilization of the corresponding phenoxyl radical via complexation with Mg(II), which is interesting for antioxidant applications. phenMgIso competes with 2,2,6,6-tetramethylpiperidine by 1O2 with IC50(1O2) = 15 μg m–1 and with nitrotetrazolium blue chloride by superoxide ions (IC50(O2•–) = 3.6 μg mL–1). Exposure of both zebrafish (2 mg L–1) and wistar male rats (3 mg kg–1 day–1 dose for 21 days) to phenMgIso does not cause mortality or visual changes compared with the respective control groups, thus phenMgIso could be considered safe under the conditions of this study. Moreover, no significant changes in comparison to both control groups were observed in the biochemical parameters on the brain-acetylcholinesterase activity, digestive tract enzyme catalase, and glutathione-S-transferase. Conversely, the performance of superoxide dismutase activity in wistar male rats increased in the presence of a complex, resulting in enhanced capacity of rats for superoxide radical enzymatic scavenging. The synergistic action of phenMgIso may be explained by the strong electrostatic interaction between Mg(II) and the O,O(phenolate) group, which makes the Iso ligand easier to oxidize and deprotonate, generating a cyclic stable species under oxidative conditions.
Parkinson's disease (PD) is a neurodegenerative disease characterized by motor symptoms and nonmotor disturbances such as fatigue, cognitive impairment, constipation, anxiety, and depression. The dopaminergic neurodegeneration is a hallmark of PD; however, the serotonergic system also presents alterations. Dorsal raphe nucleus (DRN) and median raphe nucleus (MNR) neurons are responsible for the central biosynthesis of serotonin (5-HT). We aimed to investigate whether the rotenone model would affect serotonergic neurons of the DRN and MRN and reduce 5-HT levels in target structures related to depressive-like behavior and short-term memory. Adult male Wistar rats were treated for 10 days with rotenone or sunflower oil. One day after the last rotenone injection, animals exhibited hypolocomotion in the open field. Furthermore, rotenone impaired the short-term memory assessed in the social recognition test performed 22 days after the last injection. In the forced swim test, performed on day 28, we observed depressive-like behavior, indicated by an increase in immobility time in the rotenone group. Immunohistochemical analysis revealed a reduction of serotonergic neurons in the MRN on the 28th day after the last administration of rotenone. Moreover, the ventrolateral part of DRN presented a decrease of serotonergic neurons. Neurochemical quantification revealed a reduction of serotonin levels in the prefrontal cortex and striatum, and a reduction of dopamine and noradrenaline levels in the prefrontal cortex, striatum, and amygdala. Overall, the results revealed that the development of behavioral impairments induced by systemic rotenone is involved with MRN, and likewise 5-HT, other neurotransmitters such as dopamine and noradrenaline may play a role in nonmotor disorders in the animal model of PD.